PCI Biotech to present at BIO-Europe 2017
Oslo, Norway, November 6, 2017 PCI Biotech (OSE:PCIB), a clinical-stage company developing innovative therapeutics that address significant unmet medical needs, today announced that it will present at BIO-Europe 2017 being held November 6-8, 2017 at the CityCube Berlin, Germany.
On Tuesday, November 7, 2017 at 09:30am (CET), Mr. Gaël L'Hévéder, CBDO, will present an overview of PCI Biotech's technology and the multiple business development and commercial opportunities available based on this proprietary platform. The presentation will be made available on PCI Biotech's website (
www.pcibiotech.com
) under "Other presentations".
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms:
fima
Chem
(enhancement of chemotherapeutics for localised treatment of cancer),
fima
Vacc
(T-cell induction technology for therapeutic vaccination), and
fima
NAc
(nucleic acid therapeutics delivery).
Photochemical internalisation induces triggered endosomal release that is used to unlock the true potential of a wide array of therapeutic modalities. The company's lead
fima
Chem
programme consists of a clinical Phase I/II clinical study in bile duct cancer, an orphan indication with a high unmet need and without approved products.
fima
Vacc
applies a unique mode of action to enhance the essential cytotoxic effect of therapeutic cancer vaccines, which works in synergy with several other state-of-the-art vaccination technologies.
fima
NAc
utilises the endosomal release to provide intracellular delivery of nucleic acids, such as mRNA and siRNA therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
Contact information:
PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo, Norway.
www.pcibiotech.com
Ronny Skuggedal, CFO,
rs@pcibiotech.no
, Mobile: +47 9400 5757.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: PCI Biotech Holding via GlobeNewswire